Zim LaboratoriesNSE:ZIMLAB -2.32%76 EBITDA Margin % is 12.69% as of Mar. 2026, which is 3% below its 10-year median of 13.14. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, Zim Laboratories ranks worse than 53.3% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zim Laboratories's EBITDA for the
three
months ended in Mar. 2026 was ₹134 Mil. Zim Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹1,053 Mil. Therefore, Zim Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 12.69%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zim Laboratories EBITDA Margin % Related Terms
Zim Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a EBITDA Margin % of 12.69% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zim Laboratories and its competitors. This is near median its historical median of 13.14. Over the past decade, Zim Laboratories' EBITDA Margin % has ranged from 9.88 to 16.24. According to the industry distribution chart, Zim Laboratories ranks #509 out of 955 companies in the Drug Manufacturers industry, placing it in the top 53.3%.
Is Zim Laboratories' EBITDA Margin % too high?
Zim Laboratories' current EBITDA Margin % of 12.69% is near median its 10-year median of 13.14. Over the past 10 years, this metric has ranged from a low of 9.88 to a high of 16.24. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Zim Laboratories' value of 12.69% is 2.4% above this industry median. Based on the distribution chart, Zim Laboratories ranks #509 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #509 out of 955 companies for EBITDA Margin %. This places Zim Laboratories in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Zim Laboratories' value of 12.69% is 2.4% above this benchmark. Historically, Zim Laboratories' own EBITDA Margin % has ranged from 9.88 to 16.24 over the past decade. While the company's 10-year median is 13.14 vs. the industry median of 12.39, Zim Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current EBITDA Margin % of 12.69% is 2.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current EBITDA Margin % is 12.69%, which is near median its own 10-year median of 13.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current EBITDA Margin % is 12.69%, which is near median its 10-year median of 13.14 and 2.4% above the Drug Manufacturers industry median of 12.39. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current EBITDA Margin % is 12.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
EBITDA Margin %: 12.69% (near median its 10-year median of 13.14)
GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
Industry Position: 2.4% above the Drug Manufacturers median (#509 of 955)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score
Get the complete analysis for NSE:ZIMLAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
